Market Research Report
Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023
|Published by||MarketsandMarkets||Product code||696447|
|Published||Content info||231 Pages
Delivery time: 1-2 business days
|Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023|
|Published: September 5, 2018||Content info: 231 Pages||
The cell viability assays market is expected to reach USD 4.16 billion by 2023 from an estimated USD 2.78 billion in 2018, at a CAGR of 8.4%. The rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are the key drivers for market growth. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.
On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells. The human cells segment is expected to register the highest CAGR during the forecast period. Growth in this segment is mainly due to the growing investments by government bodies and private sector organizations in research activities that are focused on developing new treatments for various human diseases.
On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. The stem cell research applications segment is expected to witness the highest CAGR owing to the increasing number of stem cell research activities and rising investments in stem cell research.
North America is expected to account for the largest share of the global cell viability assays market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing prevalence of chronic and infectious diseases in this region, large patient population, increasing healthcare spending, and growing interest of key players in APAC countries.
The breakdown of primary participants was as mentioned below:
The prominent players in the global cell viability assays market are: Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).
The report analyzes the various cell viability products and their adoption pattern. It aims at estimating the market size and future growth potential of the global cell viability assays market for different segments such as products, cell types, applications, end users, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.
This report provides insights on the following pointers:
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.